XJ 101
Alternative Names: XJ-101Latest Information Update: 23 Feb 2024
Price :
$50 *
At a glance
- Originator Starmab Biologics Shanghai
- Class Antibacterials; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Staphylococcal infections
Most Recent Events
- 28 Aug 2023 Preclinical trials in Staphylococcal infections in China (IV, Injection) prior to August (NCT06014736)
- 28 Aug 2023 Starmab biologics Shanghai plans a phase I trial for Staphylococcal infections (In volunteers) in China (NCT06014736)
- 15 Aug 2023 Phase-I clinical trials in Staphylococcal infections (In volunteers) in China (IV) (NCT06014736)